Regulation of human extracellular calcium- sensing g protein-coupled receptor
First Claim
1. An isolated polynucleotide encoding a extracellular calcium-sensing G protein-coupled receptor polypeptide and being selected from the group consisting of:
- a) a polynucleotide encoding a extracellular calcium-sensing G protein-coupled receptor polypeptide comprising an amino acid sequence selected form the group consisting of;
amino acid sequences which are at least about 35% identical to the amino acid sequence shown in SEQ ID NO;
2; and
the amino acid sequence shown in SEQ ID NO;
2. b) a polynucleotide comprising the sequence of SEQ ID NO;
1;
c) a polynucleotide which hybridizes under stringent conditions to a polynucleotide specified in (a) and (b);
d) a polynucleotide the sequence of which deviates from the polynucleotide sequences specified in (a) to (c) due to the degeneration of the genetic code; and
e) a polynucleotide which represents a fragment, derivative or allelic variation of a polynucleotide sequence specified in (a to (d).
1 Assignment
0 Petitions
Accused Products
Abstract
Reagents which regulate human extracellular calcium sensing G protein-coupled receptor and reagents which bind to human extracellular calcium-sensing GPCR gene products can play a role in preventing, ameliorating, or correcting dysfunctions or diseases including, but not limited to, obesity and diseases related to obesity, cancer, diabetes, osteoporosis, anxiety, depression, hypertension, migraine, compulsive disorders, schizophrenia, autism, neurodegenerative disorders, such as Alzheimer'"'"'s disease, Parkinsonism, and Huntington'"'"'s chorea, and cancer chemotherapy-induced vomiting.
-
Citations
71 Claims
-
1. An isolated polynucleotide encoding a extracellular calcium-sensing G protein-coupled receptor polypeptide and being selected from the group consisting of:
-
a) a polynucleotide encoding a extracellular calcium-sensing G protein-coupled receptor polypeptide comprising an amino acid sequence selected form the group consisting of;
amino acid sequences which are at least about 35% identical to the amino acid sequence shown in SEQ ID NO;
2; and
the amino acid sequence shown in SEQ ID NO;
2.b) a polynucleotide comprising the sequence of SEQ ID NO;
1;
c) a polynucleotide which hybridizes under stringent conditions to a polynucleotide specified in (a) and (b);
d) a polynucleotide the sequence of which deviates from the polynucleotide sequences specified in (a) to (c) due to the degeneration of the genetic code; and
e) a polynucleotide which represents a fragment, derivative or allelic variation of a polynucleotide sequence specified in (a to (d). - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)
-
- 18. A cDNA encoding a polypeptide comprising the amino acid sequence shown in SEQ ID NO:
- 21. An expression vector comprising a polynucleotide which encodes a polypeptide comprising the amino acid sequence shown in SEQ ID NO:
- 23. A host cell comprising an expression vector which encodes a polypeptide comprising the amino acid sequence shown in SEQ ID NO:
- 25. A purified polypeptide comprising the amino acid sequence shown in SEQ ID NO:
-
27. A fusion protein comprising a polypeptide having the amino acid sequence shown in SEQ ID NO:
- 2.
-
28. A method of producing a polypeptide comprising the amino acid sequence shown in SEQ ID NO:
- 2, comprising the steps of;
culturing a host cell comprising an expression vector which encodes the polypeptide under conditions whereby the polypeptide is expressed; and
isolating the polypeptide. - View Dependent Claims (29)
- 2, comprising the steps of;
-
30. A method of detecting a coding sequence for a polypeptide comprising the amino acid sequence shown in SEQ ID NO:
- 2, comprising the steps of;
hybridizing a polynucleotide comprising 11 contiguous nucleotides of SEQ ID NO;
1 to nucleic acid material of a biological sample, thereby forming a hybridization complex; and
detecting the hybridization complex. - View Dependent Claims (31, 32)
- 2, comprising the steps of;
-
33. A method of detecting a polypeptide comprising the amino acid sequence shown in SEQ ID NO:
- 2, comprising the steps of;
contacting a biological sample with a reagent that specifically binds to the polypeptide to form a reagent-polypeptide complex; and
detecting the reagent-polypeptide complex. - View Dependent Claims (34, 35)
- 2, comprising the steps of;
-
36. A method of screening for agents which can modulate the activity of a human extracellular calcium-sensing G protein-coupled receptor, comprising the steps of:
-
contacting a test compound with a polypeptide comprising an amino acid sequence selected from the group consisting of;
(1) amino acid sequences which are at least about 35% identical to the amino acid sequence shown in SEQ ID NO;
2 and (2) the amino acid sequence shown in SEQ ID NO;
2; and
detecting binding of the test compound to the polypeptide, wherein a test compound which binds to the polypeptide is identified as a potential agent for regulating activity of the human extracellular calcium-sensing G protein-coupled receptor. - View Dependent Claims (37, 38, 39, 40, 41, 42, 43, 44, 69)
-
-
45. A method of screening for agents which modulate an activity of a human extracellular calcium-sensing G protein-coupled receptor, comprising the steps of:
contacting a test compound with a polypeptide comprising an amino acid sequence selected from the group consisting of;
(1) amino acid sequences which are at least about 35% identical to the amino acid sequence shown in SEQ ID NO;
2 and (2) the amino acid sequence shown in SEQ ID NO;
2; and
detecting an activity of the polypeptide, wherein a test compound which increases the activity of the polypeptide is identified as a potential agent for increasing the activity of the human extracellular calcium-sensing G protein-coupled receptor, and wherein a test compound which decreases the activity of the polypeptide is identified as a potential agent for decreasing the activity of the human extracellular calcium-sensing G protein-coupled receptor.- View Dependent Claims (46, 47, 48, 70)
-
49. A method of screening for agents which modulate an activity of a human extracellular calcium-sensing G protein-coupled receptor, comprising the steps of:
-
contacting a test compound with a product encoded by a polynucleotide which comprises the nucleotide sequence shown in SEQ ID NO;
1; and
detecting binding of the test compound to the product, wherein a test compound which binds to the product is identified as a potential agent for regulating the activity of the human extracellular calcium-sensing G protein-coupled receptor. - View Dependent Claims (50, 51, 71)
-
-
52. A method of reducing activity of a human extracellular calcium-sensing G protein-coupled receptor, comprising the step of:
contacting a cell with a reagent which specifically binds to a product encoded by a polynucleotide comprising the nucleotide sequence shown in SEQ ID NO;
1, whereby the activity of a human extracellular calcium-sensing G protein-coupled receptor is reduced.- View Dependent Claims (53, 54, 55, 56, 57, 58, 59)
-
60. A pharmaceutical composition, comprising:
-
a reagent which specifically binds to a polypeptide comprising the amino acid sequence shown in SEQ ID NO;
2; and
a pharmaceutically acceptable carrier. - View Dependent Claims (61)
-
-
62. A pharmaceutical composition, comprising:
-
a reagent which specifically binds to a product of a polynucleotide comprising the nucleotide sequence shown in SEQ ID NO;
1; and
a pharmaceutically acceptable carrier. - View Dependent Claims (63, 64, 65)
-
-
66. A pharmaceutical composition, comprising:
-
an expression vector encoding a polypeptide comprising the amino acid sequence shown in SEQ ID NO;
2; and
a pharmaceutically acceptable carrier. - View Dependent Claims (67)
-
-
68. A method of treating a extracellular calcium-sensing G protein-coupled receptor dysfunction related disease, wherein the disease is selected from obesity or a disease related to obesity, cancer, diabetes, osteoporosis, anxiety, depression, hypertension, migraine, a compulsive disorder, schizophrenia, autism, a neurodegenerative disorder, or cancer chemotherapy-induced vomiting comprising the step of:
administering to a patient in need thereof a therapeutically effective dose of a reagent that modulates a function of a human extracellular calcium-sensing G protein-coupled receptor, whereby symptoms of the extracellular calcium-sensing G protein-coupled receptor dysfunction related disease are ameliorated.
Specification